Major bleeding complications related to combined antithrombotic therapy in atrial fibrillation patients 12 months after coronary artery stenting. Issue 3 (March 2015)

• Record Type: Journal Article
• Authors: Kawai, Hideki; Watanabe, Eiichi; Yamamoto, Mayumi; Harigaya, Hiroto; Sano, Kan; Takatsu, Hidemaro; Muramatsu, Takashi; Naruse, Hiroyuki; Sobue, Yoshihiro; Motoyama, Sadako; Sarai, Masayoshi; Takahashi, Hiroshi; Arakawa, Tomoharu; Kan, Shino; Sugiura, Atsushi; Murohara, Toyoaki; Ozaki, Yukio
• Is Part Of: Journal of cardiology. Volume 65:Issue 3(2015:Mar.)
• Page Start: 197
• Page End: 202
• Publication Date: 2015-03
• Subjects: Cardiology -- Periodicals; 616.12
• DOI: 10.1016/j.jjcc.2014.08.013
• Languages: English
• ISSNs: 0914-5087

Abstract

<abstract abstract-type="author" id="abs0005"> <title id="sect0005">Abstract</title> <sec> <title id="sect0010">Background and purpose</title> <p id="spar0005">Many patients with atrial fibrillation (AF) and coronary artery stent deployment are given both antiplatelet drug and warfarin. Little information is available as to the relationship between the antithrombotic therapies in the late phase after stenting and the clinical outcomes of these patients. We examined the clinical outcomes of AF patients 12 months after coronary artery stenting.</p> </sec> <sec> <title id="sect0015">Methods</title> <p id="spar0010">We retrospectively examined 146 patients and classified them into three groups according to the antithrombotic therapies [dual antiplatelet therapy (DAPT), single antiplatelet therapy (SAPT) plus warfarin, and DAPT plus warfarin] 12 months after stenting. We defined the primary endpoint as Thrombolysis in Myocardial Infarction major bleeding and the secondary endpoint as a composite of adverse events (CAE: all-cause death, nonfatal myocardial infarction, intracranial bleeding, and cerebral infarction).</p> </sec> <sec> <title id="sect0020">Results</title> <p id="spar0015">During a median follow-up of 37 months, major bleeding and CAE were observed in 14 (9.6%) and 46 (31.5%) patients, respectively. DAPT plus warfarin was an independent risk factor for major bleeding in a multivariate Cox hazard regression model after adjustment for age, gender, and the type of AF (hazard ratio: 4.20; 95% confidence interval: 1.13–17.27; <italic>p</italic> = 0.033). No significant clinical variables were found for CAE.</p> </sec> <sec> <title id="sect0025">Conclusions</title> <p id="spar0020">Prolonged use of DAPT with warfarin significantly increases the risk of major bleeding in AF patients after coronary artery stenting. Individualized antithrombotic treatment is required in these patients to prevent major bleeding.</p> </sec> </abstract>